ANYARA
Clinical experience with ANYARA (ABR-217620/CD3) and ABR-214936 (CD2)
Phase I dose escalation, pharmakokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non small-cell lung cancer. Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB, J Clin Oncol 27:4116-4123. © 2009 by American Society of Clinical Oncology.
An open label phase I study of ABR-217620 in combination with docetaxelin patients with NSCLC
Cohen RB, Borghaei H, Langer CJ, Alpaugh K, Lassen U, Afanasiev BV, Orlov SV, Yablonsky PK, Forsberg G, Hedlund G. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007 Oct 22-26; San Francisco, CA. Philadelphia (PA): AACR 2007. Abstract nr A163.
A Phase II study of a 5T4 oncofetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma
Shaw DM, Connolly NB, Patel PM, Kilany S, Hedlund G, Nordle Ö, Forsberg G, Zweit J, Stern PL and Hawkins RE, British Journal of Cancer (2007) 96, 567-574.
An open label phase I study of ABR-217620, a fusin protein of the 5T4 antibody moiety and an engineered superantigen, in patients with non-small cell lung, renal cell or pancreatic cancer
Cohen RB, Langer CJ, Alpaugh RK, Dueland S, Aamdal S, Hawkins RE, Griffiths RW, Hedlund G, Forsberg G, Kilany S. J Clin Oncol (2006) ASCO Annual Meeting Proceedings Part I. Vol 24, No 18S (June 20 Supplement), 2006:3083.
Individualized Patient Dosing in Phase I Clinical Trials: The Role of Escalation With Overdose Control in PNU-214936
Cheng J D, Babb J S, Langer C, Aamdal S, Robert F, Engelhardt L R, Fernberg O, Schiller J, Forsberg G, Alpaugh K R, Weiner L M, and Rogatko A, J Clin Oncol 22:602-609. © 2004 by American Society of Clinical Oncology
Tumor targeted superantigen therapy in advanced non-small cell lung cancer: A phase I dose escalation study of ABR-214936, anatumomab mafenatox
Aamdal S, Fernberg L, Engelhart R, Fodstad O, Forsberg G; The Norwegian Radium Hospital, Oslo, Norway; Karolinska Hospital, Stockholm,
Sweden; Albert-Ludwigs Universitat, Freiburg, Germany; Active Biotech Research AB, Lund, Sweden. Citation: Proc Am Soc Clin Oncol 22: page 179, 2003 (abstr 718)
Phase I study of anatumomab mafenatox (ABR) 214936 in adv NSCLC: Results of a multi-institutional open label repeat dose trial with pt-specific dose escalation
Alpaugh R K, Langer C J, Robert F, Schiller J, Kopreski M, Rogatko A, Forsberg G, Weiner LM; Proc Am Soc Clin Oncol 22: page 649, 2003 (abstr 2611)
Immunopharmacology and tumor models
Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects
Sundstedt A, Celander M, Wallén-Öhman M, Forsberg G, Hedlund G, Int Immunopharmacol. 2009 Aug;9(9):1063-70.
A fusion protein between 5T4 binding antibody fragment and an engineered superantigen (ANYARA) is a targeted immunotherapy effective alone and in combination with other cancer therapies.
Hedlund G, Forsberg G, Sundstedt A, Axelsson B and Celander M. IBC's 6th Annual International Conference Antibody Therapeutics. December 9-11, 2008, San Diego, CA.
Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects
Sundstedt A, Celander M, Hedlund G, Int Immunopharmacology (2008) 8, 442-452
Antibody-targeted superantigens are potent inducers of tumour-infiltrating T-lymphocytes in vivo
Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T. Proc Natl Acad Sci USA 1995, 92: 9791-5.
Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy
Dohlsten M, Abrahamsen L, Bjork P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NR, Forberg C, Lind P, Kalland T. Proc Natl Acad Sci USA (1994) 91:8945-8949.
Monoclonal antibody-targeted superantigens: a different class of anti-tumour agents
Dohlsten M, Hedlund G, Akerblom E, Lando PA, Kalland T. Proc Natl Acad Sci USA 1991, 88: 9287-91.
Superantigen and production
Identification of the Antigenic Epitopes in Staphylococcal Enterotoxins A and E and Design of a Superantigen for Human Cancer Therapy
Erlandsson E, Andersson K, Cavallin A, Nilsson A, Larsson-Lorek U, Niss U, Sjöberg A, Wallén-Öhman M, Antonsson P, Walse B and Forsberg G, J. Mol. Biol. (2003) 333, 893–905
Identification of Framework Residues in a Secreted Recombinant Antibody Fragment That Control Production Level and Localization in Escherichia coli
Forsberg G, Forsgren M, Jaki M, Norin M, Sterky C, Enhörning Å, Larsson K, Ericsson M, and Björk P, J. Biol. Chem. Vol. 272, No. 19, Issue of May 9, pp. 12430–12436, 1997
Crystal structure of a SEA variant in complex with MHC class II reveals the ability of SEA to crosslink MHC molecules
Petersson K, Thunnissen M, Forsberg G, Walse B. Structure (Camb) 2002, 10: 1619-26.
Interplay Between Superantigens and Immunoreceptors
Petersson K, Forsberg G, and Walse B, Scandinavian Journal of Immunology 59, 345–355.
5T4 - the tumor targeting antibody part
Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen
Forsberg G, Ohlsson L, Brodin T, Bjork P, Lando PA, Shaw D, Stern PL, Dohlsten M. Br J Cancer 2001, 85: 129-36.
Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4
Shaw D M;*, Embleton M J, Westwater C, Ryan M G, Myers K A, Kingsman S M, Carroll M W, Stern P L, Biochimica et Biophysica Acta 1524 (2000) 238-246.
Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen
Shaw D M, Woods A M, Myers K A, Westwater C, Rahi-Saund V, Davies M J, Renouf D V, Hounsell E F and Stern P L, Biochem. J. (2002) 363, 137-145.